Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Zevra Therapeutics Inc shares valued at $13,540 were purchased by Clifton R. LaDuane on Jul 17 ’24. At $6.77 per share, Clifton R. LaDuane acquired 2,000 shares. The insider’s holdings grew to 18,469 shares worth approximately $0.16 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Anderson Thomas purchased 10,000 shares, netting a total of over 68,065 in proceeds. Following the buying of shares at $6.81 each, the insider now holds 20,000 shares.
Before that, Bode John B had added 10,000 shares to its account. In a trade valued at $58,661, the Director bought Zevra Therapeutics Inc shares for $5.87 each. Upon closing the transaction, the insider’s holdings increased to 10,000 shares, worth approximately $0.25 million.
As published in their initiating research note from Guggenheim on October 07, 2024, Zevra Therapeutics Inc [ZVRA] has been a Buy and the price target has been revised to $20. Analysts at Maxim Group resumed the stock at ‘”a Buy”‘ outlook in a report released in late September. As of September 24, 2024, JMP Securities has initiated its “Mkt outperform” rating for ZVRA. Earlier on April 02, 2024, Maxim Group resumed its rating. Their recommendation was “a Buy” for ZVRA stock.
Analyzing ZVRA Stock Performance
During the last five days, there has been a surge of approximately 18.96%. Over the course of the year, Zevra Therapeutics Inc shares have jumped approximately 29.31%. Shares of the company reached a 52-week high of $8.95 on 09/20/24 and a 52-week low of $4.20 on 07/05/24. A 50-day SMA is recorded $7.33, while a 200-day SMA reached $5.93. Nevertheless, trading volume fell to 1.43 million shares from 1.46 million shares the previous day.
Support And Resistance Levels for Zevra Therapeutics Inc (ZVRA)
According to the 24-hour chart, there is a support level at 8.15, which, if violated, would cause prices to drop to 7.82. In the upper region, resistance lies at 8.74. The next price resistance is at 9.00. RSI (Relative Strength Index) is 64.50 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.67, which suggests the price will decrease in the coming days. Percent R is at 20.51%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
